In an era of reckoning, more people have been coming forward about church sexual abuse.…
Johnson & Johnson has agreed to pay more than $100 million to resolve more than 1,000 lawsuits alleging the company’s talc-based baby powder led to ovarian cancer.
It is a signal that the largest maker of health care products is trying to get ahead of the rapidly increasing ovarian cancer litigation. There are still about 20,000 lawsuits pending.
This is the first time Johnson & Johnson has settled the bulk of a plaintiffs lawyer’s cases concerning its dangerous baby powder product.
The news comes seven months after Johnson & Johnson was hit with a $186 million jury verdict for punitive damages. Johnson & Johnson pulled their talc-based baby powder from the U.S market in May of this year. Currently, the only version of baby powder selling in the U.S. and Canada is made from cornstarch.
According to anonymous sources, the company used the pandemic’s silence to hold off any talks about settlements. However, the pause comes to an end as a trial scheduled from a factory worker that tied mesothelioma to talc starts this month in California.
Does a settlement mean J&J admitting fault for baby powder cancer claims?
According to Kim Montagnino, a J&J spokeswoman said that the company chooses to settle in certain circumstances but in no way changes their position in regards to the safety of their products. She added that the product didn’t contain asbestos and doesn’t cause cancer.
In July, Bloomberg Intelligence estimated that settling all the cases could cost J&J as much as $10 billion.
We care, we can help
The Carlson Law Firm is accepting clients who have been diagnosed with ovarian cancer after using Johnson & Johnson talc-based products. If you’ve developed ovarian cancer and have used Johnson & Johnson Baby Powder or Shower to Shower, contact The Carlson Law Firm today at 800-359-5690.
Our firm has more than 40 years of experience helping those injured by dangerous products navigate the legal to get the compensation they deserve.